CK-isoenzymes
(including macro-CK)
Material: | 1 ml serum |
Methods: | Elektrophorese → Elektrophorese | Reference range | CK-BB (brain type): 0 % CK-MB (myocardial type): with a total activity between 15 and 500 U/l: < 3 % with a total activity over 500 U/l: < 4 % CK-MM (muscular type): 97 – 100 % Macro-CK type 1: 0 % Macro-CK type 2: 0 % |
Indication | Differential diagnosis of serum CK increase, suspicion of macro-CK |
Please note | CK-MM originates from skeletal muscle. It is increasingly released after muscular spasms, trauma, surgery, intramuscular injections, arterial embolism, myositis and muscle dystrophy. CK-MB is detectable in case of myocardial damage. CK-BB activity is found in ischemia of the brain and in diseases of various inner organs (gastro-intestinal tract, lungs, kidneys). In older patients, mainly women, with an incidence of approximately 3 %, macro-CK development can be seen; its pathophysiological significance is yet unknown. Macro-CK type 1 is a CK-BB IgG or CK-MM IgA immune complex with moderate total CK increase and without clinical significance. The macro-CK type 2 as an epiphenomenon is only seen in severely ill patients (tumors, liver cirrhosis etc.) and is a multimeric mitochondrial CK (CK-Mi). |
Accredited | ja |
More Results for the letter A
- Angina Plaut-Vincenti (APV)
- Treponema vincentii and fusobacterium nucleatum
- ANP (ANP)
- atrial natriuretic peptide
- Anti-actin autoantibodies (ACTIN)
- Anti-alpha fodrin autoantibodies (AFODG)
- Anti-desmoglein 1/3 (DESMO)
- Anti-DNA antibodies (DNADS)
- ds-DNA antibodies (double-stranded)
- Anti-epidermal basal membrane (EPI)
- Anti-goblet cell autoantibodies (BECZE)
- Anti-mitochondrial antibodies (AMA)
- AMA and AMA subtype 2
- Anti-mullarian hormone (AMH)
- Anti-sickle cell desmosomes (STADE)
- Anti-SP100 (SP100)
- multiple nuclear dots
- Antibiogram (ANTIBIO)
- Antibodies against α-amino-3-hydroxy-5-methyl-4-isoxazol-propionic acid receptor (AMPAR)
- Antibodies against adenylate kinase 5 (Ak5)
- Ak5
- Antibodies against contactin-associated protein 2 (CASPR2)
- Antibodies against ganglionic (alpha-3) acetylcholine receptors (gAChR)
- (gAChR)
- Antibodies against glutamate decarboxylase 65 kDa (GAD65)
- Antibodies against leucine-rich glioma inactivated protein 1 (LGI1)
- Antibodies against LRP4
- (low-density lipoprotein receptor-related protein 4)
- Antibodies against myelin oligodendrocyte glycoprotein (MOG)
- Antibodies against N-methyl-D-aspartate receptor receptors (NMDAR)
- Antibodies against oxidized LDL (LDLOX)
- Antibodies against the γ-aminobutyric acid A receptor (GABA-A-R)
- Antibodies against the γ-aminobutyric acid B receptor (GABA-B-R)
- Antibodies against the glial fibrillary acidic protein (GFAP)
- Antibodies against the glycine receptor (GlyR)
- Antibodies against the metabotropic glutamate receptor type 1 (mGluR1 antibodies)
- Antibody screen (ANTI01)
- Antibody screening (AK)
- AKS